# Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals

> **NCT00813228** · PHASE1 · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 76 (actual)

## Conditions studied

- Diabetes Mellitus Type 1
- Diabetes Mellitus Type 2

## Interventions

- **DRUG:** Sitagliptin (Januvia)

## Key facts

- **NCT ID:** NCT00813228
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01-06
- **Primary completion:** 2019-11-26
- **Final completion:** 2019-11-26
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2019-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00813228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00813228, "Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00813228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*